作者: Thierry Guillaume , Daniel B. Rubinstein , Michel Symann
关键词:
摘要: APPROXIMATELY 10,000 autologous hematopoietic stem cell (HSC) transplants are performed worldwide each year for malignant diseases.[1][1] Results of randomized trials in recent years suggest that high-dose chemotherapy followed by infusion HSCs can offer prolonged disease-free survival